Ensysce Biosciences Inc.
1430 O'Brien Drive
28 articles with Ensysce Biosciences Inc.
Ensysce Biosciences, Inc. And Leisure Acquisition Corp. Announce Appointment Of Dave Humphrey As Chief Financial Officer
Ensysce Biosciences Inc. ("Ensysce"), a clinical stage pharmaceutical company developing medicines for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, and Leisure Acquisition Corp. (NASDAQ: LACQ) ("LACQ") today announced the appointment of David Humphrey to Ensysce's management team as its Chief Financial Officer.
Ensysce Biosciences, Inc. And Leisure Acquisition Corp. To Host Investor Call Regarding Business Combination On February 3, 2021
- Ensysce Biosciences, a clinical stage biopharmaceutical company with a mission to solve prescription drug abuse, is focused on launching a new class of opioid pain therapeutics
Ensysce Biosciences, a California Based Biotech With a Mission to Solve the Opioid Crisis, Secures $60 Million Capital Commitment From Global Emerging Markets
Ensysce Biosciences Inc. is a clinical phase company launching two new classes of novel opioids designed to treat severe pain, and eliminate opioid misuse, abuse and overdose. Today Ensysce announced that it has signed an agreement with GEM Global Yield LLC SCS, (GEM) a Luxembourg-based private, alternative investment group. Under the
COVISTAT, a Subsidiary of Ensysce Biosciences Inc, a California Based Company With a Mission to Solve the Opioid Crisis, Is Commencing Phase 1 Study of Novel COVID-19 Treatment
COVISTAT Inc. and its parent company Ensysce, received IND allowance and today initiated a Phase 1 clinical trial of oral nafamostat in healthy volunteers. Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysce’s opioid overdose protection platform, is being developed as an oral treatment for COVID-19. Th
Ensysce Biosciences, a California Based Biotech With a Mission to Solve the Opioid Crisis, Announces Steven R. Martin to Join Board of Directors
Ensysce Biosciences Inc., a clinical stage company launching new solutions for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, today announced the appointment of Steven R. Martin to its Board of Directors. Mr. Martin is Senior VP and Chief Financial Officer of Armata Pharmaceuticals, Inc. (NYSE: ARMP
Ensysce, a California Based Biotech Company With a Mission to Solve the Opioid Crisis, Exploring a Treatment for COVID-19.
Ensysce Biosciences is working to launch an immediate clinical trial for COVID-19 treatment.
Ensysce Biosciences Inc., a clinical phase company with innovative solutions for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, today announced the appointment of Andrew K. Benton to its Board of Directors
Ensysce Biosciences Receives Multi-Year NIH HEAL Grant to Develop a Novel Opioid-Use-Disorder (OUD) Medication
Company proprietary TAPP and MPAR overdose technology to aid a most vulnerable patient population.
Ensysce Biosciences, Inc., a clinical stage drug delivery company, focusing on reducing deaths from opioid use, today announced that D. Lynn Kirkpatrick, Ph.D., Chief Executive Officer, will present at the Janney Healthcare Conference 2019 in New York on Monday September 9,
Ensysce Biosciences to Present Novel TAAPTM and MPARTM Opioid Technology at SMi 19th Annual Pain Therapeutics Conference May 14, 2019
Ensysce Biosciences Inc., a clinical phase drug development company with innovative technologies to curb prescription drug abuse and overdose, today announced D. Lynn Kirkpatrick, Ph.D., Chief Executive Officer, will present at the upcoming 19th Annual Pain Therapeutics Conference in London UK.
Ensysce is developing proprietary TAAPTM/MPARTM prodrug delivery and overdose technology to stem the opioid abuse epidemic
Ensysce Biosciences to Participate in New Generation Analgesics Symposium at Annual Meeting of the College on Problems of Drug Dependence
Ensysce Biosciences, Inc. announced that D. Lynn Kirkpatrick, Ph.D., Chief Executive Officer, will be an invited speaker at the upcoming symposium titled New Generation Analgesics at the 80th Annual Meeting of the College on Problems of Drug Dependence (CPDD 2018).
Ensysce Biosciences Inc. Receives Fast Track Designation for PF614, BIO-MD Abuse Deterrent Extended Release Oxycodone Prodrug
Ensysce Biosciences Inc. is pleased to announce that the FDA has granted Fast Track designation for the development of PF614 for management of moderate to severe chronic pain when a continuous, around-the-clock analgesic is needed for an extended period of time.
Ensysce Biosciences to Present at Human Abuse Liability & Abuse-Deterrent Formulations Conference in Bethesda, Maryland on November 6th and 7th
The conference will provide information and training to participants on topics such as: preclinical development of abuse-deterrent drugs and delivery mechanisms, clinical trial design, and building strong, reliable networks with every stakeholder throughout the regulatory and market access community.
Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series To End The Opioid Crisis: Development Of Safe, Effective, Non-Addictive Pain Treatments
Ensysce Biosciences Inc. Publishes Manuscript Describing The In Vitro Abuse Deterrence Of Oxycodone Prodrug, PF614
Ensysce Biosciences Inc. To Present Initial Phase 1 Data On Abuse Deterrent Opioid, PF614, At Biotech Showcase 2017
Ensysce Biosciences Inc. Initiates Phase 1 Clinical Trial To Study PF614, BIO-MD Prodrug Of Oxycodone